R. B.
October 2007
Red Herring;10/7/2007, Vol. 4 Issue 29, p60
Trade Publication
The article features Research Triangle Park, North Carolina-based InnerPulse, a technology company included in "Red Herring's" top 100 list for 2007. Daniel Pelak is the chief executive officer (CEO) of the company, which has 38 employees. Some of its key investors are Johnson & Johnson Development, Medtronic and Delphi Ventures. The company is developing a new breed of implantable defibrillator as slender as a pen. The small size allows for it to be inserted through the groin and then guided close enough to the heart for a lead to be extended up to deliver the required shock. But competition is afoot, InnerPulse will have to face off with San Clemente, California-based startup Cameron Health, which is also working to bring to market a similar implantable defibrillator.


Related Articles

  • InnerPulse garners $50 million in 'C' round.  // Cardiovascular Device Update;Feb2007, Vol. 13 Issue 2, p17 

    The article reports on the closing of a $50 million equity financing of InnerPulse, a developer of technologies for the treatment of abnormal heart rhythms. The capital will be used for the completion of the company's Percutaneous Implantable Cardioverter Defibrillator (PICD). Investors in the...

  • Automated implantable cardioverter defibrillator procedure performed at Kingston Hospital.  // Hudson Valley Business Journal;6/30/2008, Vol. 19 Issue 26, p20 

    The article reports that the first automated implantable cardioverter defibrillator procedure was carried out at The Kingston Hospital in Ulster County, New York. Carmine Sorbera, chief electrophysiologist at Westchester Medical Center and New York Medical College, was the first to perform the...

  • Biotronik launches Lumax, Linoxsmart S DX systems.  // Medical Device Daily;6/27/2011, Vol. 15 Issue 118, p1 

    The article focuses on the plan of Biotronik to launch the Lumax 540 VR-T DX single-chamber implantable cardiac defibrillator (ICD) and Linoxsmart DX cardiac lead system at the 2011 EHRA Eurospace electrophysiology congress. Particular focus is given to how the Lumax DX system enhances the...

  • Singapore's high GDP translates to excellent healthcare outcomes. GROSS, AMES // Medical Device Daily;6/3/2013, Vol. 17 Issue 106, p1 

    The article focuses on Singapore's high gross domestic product (GDP) and how it translates into excellent healthcare outcomes. In 2012, the country's GDP was at nearly 300 billion U.S. dollars. The availability of high quality medical services and the promotion of preventive care have allegedly...

  • St. Jude's Fortify and Unify devices launched in Japan.  // Medical Device Daily;6/22/2011, Vol. 15 Issue 115, p1 

    The article reports on the launch by St. Jude Medical of the Fortify ST implantable cardioverter defibrillators (ICD) and Unify cardiac resynchronization therapy defibrillator (CRT-D) in Japan after receiving regulatory approval from the Japanese Ministry of Health. The Saint Paul,...

  • FDA approves new CRT-D and ICDs from Medtronic. PEDERSEN, AMANDA // Medical Device Daily;5/7/2013, Vol. 17 Issue 88, p1 

    The article reports on the approval from the U.S. Food and Drug Administration (FDA) received by U.S. firm Medtronic for its Viva portfolio of cardiac resynchronization therapy with defibrillation (CRT-D) devices and Evera implantable cardioverter defibrillators (ICD) in May 2013. The CRT-D...

  • St. Jude gets FDA approval for next-gen Ellipse, Assura ICDs. FORD, OMAR // Medical Device Daily;6/13/2013, Vol. 17 Issue 114, p1 

    The article reports on the approval received by St. Jude Medical (SJM), a developer of medical technology and services in Minnesota, from the U.S. Food and Drug Administration (FDA) for its implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy defibrillators...

  • Some 'shocking' trends in new ICD product development. Brosky, John // Medical Device Daily;9/6/2012, Vol. 16 Issue 173, p2 

    The article offers insights from physician Karl-Heinz Kuck of St. Georg Hospital in Hamburg, Germany about new implantable cardiac defibrillator (ICD) development. According to Kuck, there is a possibility of complications in the lead used in ICD. He says faulty insulation is one of several...

  • FDA clears Tyrx's resorbable AIGISRx envelope for CIEDs. PEDERSEN, AMANDA // Medical Device Daily;7/10/2013, Vol. 17 Issue 131, p1 

    The article reports on the U.S. Food and Drug Administration (FDA) clearance obtained by Tyrx in New Jersey in 2013 to market its fully resorbable AIGISRx Antimicrobial Envelope for use with pacemakers and implantable cardioverter defibrillators (ICDs). It states that the product is intended to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics